Aliases:This biomarker is also known as:
- MLN 62,
- malignant 62,
- cysteine-rich domain associated with RING and Traf domains protein 1,
- metastatic lymph node gene 62 protein,
- tumor necrosis receptor-associated factor 4A,
- RING finger protein 83,
- Cysteine-rich domain associated with RING and Traf domains protein 1,
- Metastatic lymph node gene 62 protein,
- cysteine-rich domain associated with ring and TRAF domain,
- TNF receptor-associated factor 4,
TRAF4 is a member of the TNF receptor associated factor (TRAF) family. Members of the TRAF family are the major signal transducers for the TNF receptor (TNFR) superfamily and the interleukin-1 receptor/Toll-like receptor superfamily. TRAF4 is involved in the activation of NF-kappa-B and JNK, and in the regulation of cell survival and apoptosis.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
The TRAF4 gene is amplified in breast carcinoma. TRAF4 is also involved in the regulation of the TGF-Î² pathway and in subsequent breast cancer pathogenesis.
TRAF4 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Expression and anti-apoptotic function of TRAF4 in human breast cancer MCF-7 cells.
- TRAF4 promotes TGF-Î² receptor signaling and drives breast cancer metastasis.